Anna Birna Almarsdottir
Overview
Explore the profile of Anna Birna Almarsdottir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gunnthorsdottir I, Almarsdottir A, Andersen K, Gunnarsdottir A, Svansdottir E, Einarsson H, et al.
Clin Pharmacol Ther
. 2024 Dec;
PMID: 39696763
Adhering to medication regimens is key behavior to alleviate symptoms and slow disease progression in heart failure (HF). This study explores cardiac healthcare providers' perceptions and experiences of factors influencing...
2.
van Vliet E, Lipovec N, van der Goot M, Abtahi S, Ribeiro-Vaz I, Poplavska E, et al.
Pharmacoepidemiol Drug Saf
. 2024 Nov;
33(12):e70057.
PMID: 39586738
Purpose: The European Medicines Agency (EMA) issued regulatory actions and communications in 2021 on thrombosis with thrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines Vaxzevria or Jcovden. This study aimed...
3.
Mollebaek M, Gardarsdottir H, Bikou A, Kodric A, Silva A, Andersen A, et al.
Drug Saf
. 2024 Nov;
48(2):161-177.
PMID: 39570566
Introduction: Risk minimisation measures (RMMs) aim to ensure safe use of medicines, but their implementation in clinical practice is complicated by the diversity of stakeholders whose clinical decision making they...
4.
Backran D, Ahmad S, Hansen J, Almarsdottir A, Jacobsen R
Pharmacoepidemiol Drug Saf
. 2024 Oct;
33(10):e70023.
PMID: 39375989
Purpose: We aimed to investigate the awareness of oral retinoid teratogenicity and the adherence to the pregnancy prevention program (PPP) related to oral retinoid use by physicians, pharmacists, and patients...
5.
Ballegaard E, Carlson N, Buus Jorgensen M, Sorensen I, Trankjaer H, Almarsdottir A, et al.
Clin Kidney J
. 2024 Jul;
17(7):sfae158.
PMID: 38979108
Background: Although cardiovascular morbidity and mortality are substantial in patients with chronic kidney disease (CKD), guideline-directed treatment of cardiovascular risk factors remains a challenge. Methods: Observational, cross-sectional study including patients...
6.
Hameen-Anttila K, Almarsdottir A
J Pharm Policy Pract
. 2024 Jun;
17(1):2360481.
PMID: 38845623
No abstract available.
7.
Buhl C, Jacobsen R, Almarsdottir A, Abtahi S, Andersen A, Deligianni E, et al.
Vaccine
. 2024 Jan;
42(3):556-563.
PMID: 38182460
Objective: In 2021, thrombosis with thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines Vaxzevria® and Jcovden®....
8.
Bissenbakker K, Almarsdottir A, Moller A, Schiotz M
Ugeskr Laeger
. 2023 Oct;
185(42).
PMID: 37897378
Patients living with multimorbidity, and polypharmacy can have difficulties handling the treatment burden they face daily. They often experience disjointed treatment courses and demand a more holistic approach to their...
9.
Korup S, Almarsdottir A, Magnussen L
Int J Clin Pharm
. 2023 Apr;
45(4):884-892.
PMID: 37081169
Background: Risk prioritisation algorithms provide patients with a risk category that guides pharmacists to choose those needing medication reviews (MRs) the most. For this study the Medicine Risk Score (MERIS)...
10.
Stegemann S, Almarsdottir A, Vermehren C
Eur J Pharm Biopharm
. 2023 Feb;
185:1-4.
PMID: 36801478
In recent years, the term "patient engagement" has found its way into healthcare and specifically into the field of drug development. To better understand the actual status of "patient engagement"...